This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Evolva Holding SA
Drug Names(s): AR-100, Ro 48-2622 (Oral)
BioMedTracker has separate drug entries for the oral and IV formulations of Iclaprim. Please also see Iclaprim (IV).
Iclaprim is a novel diaminopyrimidine, specific and selective inhibitor of microbial dihydrofolate reductase (DHFR). It has demonstrated potent activity against a broad spectrum of Gram-positive bacteria, including MRSA (methicillin-resistant Staphylococcus aureus) and S.aureus that exhibit reduced susceptibility (VISA) and resistance (VRSA) to standard of cure therapy vancomycin. It is also active against several important Gram-negative and intracellular pathogens. Iclaprim is rapidly bactericidal and therefore is able to actively kill pathogens, rather than just stopping their growth. Furthermore, it penetrates well into tissues that often harbor difficult to treat bacterial pathogens.
Roche and Arpida
In November 2001, Roche and Arpida have entered into a sales and purchase agreement where Arpida will receive exclusive world-wide rights for the development and commercialisation of Iclaprim. Under the terms of the agreement, all patent rights will be transferred to Arpida. Consequently, Arpida shall have exclusive world-wide commercialisation rights and will be responsible for future development and clinical registration. In exchange, Roche will receive a consideration based on future sales.
Arpida and Evolva
In September 2009, Arpida and Evolva announced that the Companies intend to merge subject to definitive agreement and shareholder approval. The merger closed in December 2009.
Partners: Roche Holding AG
Iclaprim (Oral) News
Additional information available to subscribers only: